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CXCR1, a receptor for interleukin-8 (IL-8), plays an important role in defending against pathogen
invasion during neutrophil-mediated innate immune response. Human CXCR1 is a G protein-
coupled receptor (GPCR) with its characteristic seven transmembrane domains (TMs). Functional
and structural analyses of several GPCRs have revealed that conserved residues on TM3 (including
the highly conserved Asp-Arg-Tyr (DRY) motif) and TM6 near intracellular loops contain domains
critical for G protein coupling as well as GPCR activation. The objective of this study was to elucidate
the role of critical amino acid residues on TM3 near intracellular loop 2 (i2) and TM6 near
intracellular loop 3 (i3), including S1323.47 (Baldwin location), D1343.49, M2416.34, and F2516.44, in
G protein coupling and CXCR1 activation. The results demonstrate that mutations of D1343.49 at
DRY motif of CXCR1 (D134N and D134V) completely abolished the ligand binding and functional
response of the receptor. Additionally, point mutations at positions 241 and 251 between TM6
and i3 loop generated mutant receptors with modest constitutive activity via Ga15 signaling
activation. Our results show that D1343.49 on the highly conserved DRY motif has a distinct role
for CXCR1 compared to its homologues (CXCR2 and KSHV-GPCR) in G protein coupling and receptor
activation. In addition, M2416.34 and F2516.44 along with our previously identiﬁed V2476.40 on TM6
are spatially located in a ‘‘hot spot’’ likely essential for CXCR1 activation. Identiﬁcation of these
amino acid residues may be useful for elucidating mechanism of CXCR1 activation and designing
speciﬁc antagonists for the treatment of CXCR1-mediated diseases.
 2015 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction IL-8, can not only bind to CXCR1, but also to its homologuesCXCR1 is an important member of the chemokine receptor fam-
ily that mediates migration of neutrophils primarily, but is also
important for acute and chronic inﬂammation, proliferation and
development of lymphocytes [1,2]. Its most important ligand,CXCR2 and KSHV-GPCR [3]. CXCR1 and CXCR2 share 76% amino
acid identity [1,2], are highly expressed on the surface of neu-
trophils and can trigger chemotactic signals in neutrophils in
response to IL-8. Despite their high homology and similar
co-expression on neutrophil that mediates chemotaxis, sequence
differences between CXCR1 and CXCR2 lead to distinct activation
patterns and subsequent regulation of physiological and
pathophysiological processes involved in inﬂammation and cell
proliferation. CXCR1 is speciﬁc for IL-8, whereas CXCR2 also binds
to other CXC chemokines, and differential activation and regulation
of CXCR1 and CXCR2 by IL-8 monomer and dimer have been
demonstrated [4]. IL-8 promotes bacterial killing by neutrophils
via CXCR1 but not CXCR2 at the site of inﬂammation [5], and
impairment of CXCR1 increases susceptibility to bacterial infection
[6]. Although both CXCR1 and CXCR2 promote tumor growth and
angiogenesis, it is noteworthy that only CXCR2 plays an important
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melanoma cells [7,8], and that CXCR1 blockade selectively depletes
human breast cancer stem cells [9]. Interestingly, only CXCR2 can
mediate the initial recruitment of neutrophils from the circulation
[5] and from the bone marrow [10] as well as induce senescence in
primary cells [11]. Efforts to elucidate the role of CXCR1 in vivo
have been hampered for the following reasons: (1) the lack of
speciﬁc CXCR1 agonists and antagonists, (2) human homologue
of IL-8 does not exist in mice and (3) CXCR1 is not expressed in
mouse neutrophils [12].
CXCR1 is a member of class A rhodopsin-like GPCRs, the largest
class of integral membrane proteins responsible for cellular signal
transduction as well as targeted as drug receptors [13,14]. In order
to design speciﬁc antagonists for CXCR1 and CXCR2 that would
have therapeutic beneﬁts, it is essential to understand the struc-
tural and functional differences between the CXCR homologues.
Despite recent progress on human CXCR1 structure determined
by NMR spectroscopy [15], structural information on CXCR1 such
as ligand speciﬁcity, selectivity, G protein coupling, and receptor
activation is incomplete because the crystal structure of CXCR1,
especially ligand-bound and/or G protein-bound forms, has not
been available. However, recently published crystal structures of
several other activated or inactive GPCRs have provided valuable
information applicable for GPCR activation in general. For example,
structural studies on CXCR4 and other GPCRs have indicated that
TM3 and TM6 are critical regions for signaling mechanism
[16–18]. Similar observations of agonist-bound structure of human
A2A adenosine receptor and rhodopsin have shown that an
outward tilt and rotation of the cytoplasmic half of TM6 and axial
movement of TM3 toward the extracellular side are characteristic
features of the active form of the receptor that is conformationally
capable of coupling to G protein [19,20]. The movement of TM3
and TM6 at the cytoplasmic side of the membrane is a necessary
step for GPCR activation [16–21] and constraint of the relative
mobility of the cytoplasmic end of TM3 and TM6 maintains theFig. 1. Two-dimensional diagram of human CXCR1. Most rhodopsin-like GPCRs have
characteristic seven transmembrane helices (TM1–TM7) connected by three extracellula
(S1323.47, D1343.49, M2416.34 and F2516.44) that were targeted for mutagenesis in TM3 and
(gold), formed by Cys110/Cys187 are indicated by ‘‘S–S’’.receptor in the inactive state [16–21]. Due to their importance it
is likely that disruption of these structures would likely affect G
protein binding and activation. The movement of transmembrane
helices due to ligand binding renders some amino acid residues
exposed to G protein and results in receptor activation. The
movement of TMs also induces changes in conformational
structure of the intracellular loops (especially loops i2 and i3) that
are crucial for G-protein interactions [22].
Two important domains on TM3 and TM6 involved in interac-
tion with G proteins have been identiﬁed based on crystal GPCR
structures and mutagenesis data, the speciﬁc region on TM3 near
the second intracellular loop (including the highly conserved
DRY motif) and region on TM6 near the third intracellular loop
[16–20]. In the current study, several potentially important amino
acid residues on TM3 and TM6 near the intracellular loops that
may be important for G protein coupling, including S1323.47and
D1343.49 on TM3, and M2416.34 and F2516.44 on TM6, have been
investigated. Previous data suggest that these speciﬁc residues on
TM3 and TM6 are critically involved in the GPCRs coupling to G
proteins. For example, substitution of S1203.47 with A (S120A) in
M1 muscarinic acetylcholine receptor (S132A in CXCR1) leads to
constitutive activation of the receptor [23]. D1343.49 is another
residue for which the role of DRY in G protein coupling and
receptor activation has been studied in two CXCR1 homologues,
CXCR2 and KSHV-GPCR. Despite the high conservation of DRY
motif at the junction of the third transmembrane domain to the
second intracellular loop, the KSHV-GPCR contains a VRY sequence
instead. The KSHV-GPCR exhibits constitutive signaling via
activation of PLC in the absence of ligand [24–26] which is thought
to play a role in the pathogenesis of Kaposi’s sarcoma [27,28].
Likewise, exchange of Asp1383.49 of the DRY sequence in CXCR2
with a Val (D138V), the corresponding amino acid in KSHV-GPCR,
results in constitutive activity in inositol phosphate accumulation
[25] and leads to altered activity similar to that seen in
KSHV-GPCR [29]. In alpha1B-adrenergic receptor, mutation ofa conserved Asp-Arg (DR) pair at the cytoplasmic end of TM3. CXCR1 consists of
r loops (e1e3) and three intracellular loops (i1i3). The positions of the residues
TM6 of the CXCR1 are indicated by ﬁlled circles. The putative two disulphide bonds
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activity of the receptor [30]. Lastly, the phenylalanine at TM6.44
(corresponding to F2516.44 on CXCR1) is located in the central
region of TM6 and highly conserved in 91% of the members of
the rhodopsin family of GPCRs. TM6.44 (D633 on TSH receptor)
[31,32] and D578 on LH receptor [33–35] are key switch residues
involved in activation. Several naturally occurring mutations in
TM6.44 (D578 in human luteinizing hormone receptors (LHR) such
as D578H) are associated with constitutive activation of the recep-
tor [34]. In addition, it has been suggested that the formation of a
salt bridge between helices 3 (L457) and 6 (D578) is responsible for
the constitutive activity of the naturally occurring L457R mutation
of the human lutropin receptor [33]. Similarly, naturally occurred
D633A, F, H mutation in TM6.44 of TSH receptor lead to high con-
stitutive activation [31,32]. As these amino acid residues are rela-
tively conserved in all GPCRs rhodopsin family, we sought to
determine if these residues on TM3 and TM6 of human CXCR1
are involved in the interaction between receptor and G proteins.
Our results show that mutant M241V and F251H are constitutively
active mutants coupled to G proteins and lead to increase in IP
accumulation in the absence of the ligand IL-8, suggesting an
important role of these residues in G protein coupling of CXCR1.
2. Results
2.1. Construction of CXCR1 mutations by site-directed mutagenesis
CXCR1 is a member of rhodopsin-like GPCRs (Fig. 1). To eluci-
date the role of the highly conserved DRY motif in activation and
function of CXCR1, we introduced a mutation in D1343.49 of DRY
motif of CXCR1. Other amino acid residues on TM3 and TM6 poten-
tially involved in G protein coupling and constitutive activity of
GPCRs that were studied include S132 (TM3:47), M241 (TM6:34)
and F251 (TM6:44). Among four amino acid residues chosen for
our study, D1343.49 and F2516.44 are highly conserved whereasFig. 2. Color scheme showing alignment of amino acid conservation for CXCR1 and othe
scoring scheme works from 0 for the least conserved alignment position up to 10 for the
amino acid residues subjected to mutagenesis (S1323.47, D1343.49, M2416.34 and F2516.4S1323.47 and M2416.34 are modestly conserved (Fig. 2). Selective
mutations were made because of their critical roles in G protein
coupling in several other GPCRs. These CXCR1 mutants were
expressed in COS-7 cells or HEK239 cells and their expression,
binding of IL-8, and Ga15- and Gai coupling-induced IP production
were determined.
2.2. Expression of CXCR1 and its mutants
The ﬂow cytometry data demonstrated the expression of WT
CXCR1 and mutants on transfected HEK293 cells (Fig. 3A and B)
except F251A which was barely expressed. The surface expression
of CXCR1 and its mutants were further supported by confocal
imaging results (Fig. 4). Consistently, F251A mutant was poorly
expressed, whereas other mutants, including S132A, D134N,
D134V, M241V, F251H, and F251Y, were detectable on the cell
surface (Figs. 3A, B, and 4).
2.3. Ligand binding assay of CXCR1 and its mutants
Results of the ligand binding assay are summarized in Table 1
and Fig. 5. Mutant receptors S132A, F251H, and F251Y
showed similar afﬁnity constant to WT (4.15e–09 M, 4.86e–09 M,
3.48e–09 M vs. 5.55e–09 M of WT), whereas mutants F251A and
M241V exhibited increased Kd values vs. WT (1.03e–09 M and
1.53e–09 M vs. 5.55e–09 M of WT). The antibody (anti-CD128a)
utilized for both ﬂow cytometry and confocal microscopy
speciﬁcally recognizes NH2 terminus of CXCR1. Previously we
demonstrated that conformational changes seen in the CXCR1
mutants can affect both their ability to bind to speciﬁc ligand
(ligand binding assay) and their speciﬁc recognition by the same
anti-CD128a CXCR1 antibody (ﬂow cytometry and confocal
microscopy) [36]. In agreement with this, although both D134N
and D134V mutants were expressed on the surface of transfected
cells (as determined by ﬂow cytometry and confocal microscopy)r rhodopsin family GPCRs. The conservation scoring is performed by PRALINE. The
most conserved alignment position, as indicated by the color assignments. The four
4) are highlighted with open bars.
Fig. 3. Flow cytometry of CXCR1 WT and mutants. HEK 293 cells were transiently transfected with CXCR1 or its mutants. Cells were incubated with FITC-conjugated mouse
anti-human CD181 (CXCR1). Speciﬁcity of signal was conﬁrmed by staining the cells with mouse IgG1 isotype control. (A) Transfected HEK 293 cell population stained
positive using the anti-CXCR1 antibody (M2 region). (B) Fluorescence of positively stained cells were quantiﬁed by FACS (n = 3, mean ± SEM, with CXCR1 WT set to 100%).
Fig. 4. Confocal analysis of expression of CXCR1 and its mutants. Surface expression
of CXCR1 and its mutants on COS-7 cells were measured as described. The green
color represents the surface expression of CXCR1. The cells were counterstained
with Dapi as shown in blue.
Table 1
Summary of ligand binding assay of CXCR1 WT and mutants.1
CXCR1
Residue
Location
(Baldwin#)
CXCR1 and
Mutants
Bmax (% of
WT)
Kd (M)
WT 100 ± 0 5.550e09
(4.401e009 to
7.000e009)
Ser 132 TM3,
residue 47
S132A 179.6 ± 27.7 4.154e09
(3.523e009 to
4.897e009)
Asp 134 TM3,
residue 49
D134 N 18.8 ± 2.0 N.D.
D134V 19.5 ± 0.5 N.D.
Met 241 TM6,
residue 34
M241V 160.8 ± 13.3 1.531e09
(1.068e009 to
2.194e009)
Phe 251 TM6,
residue 44
F251A 30.2 ± 5.2 1.026e09
(8.500e010 to
1.238e009)
F251H 256.9 ± 0.8 4.860e09
(4.434e009 to
5.328e009)
F251Y 213.0 ± 6.9 3.478e09
(2.816e009 to
4.294e009)
1 Bmax and Kd value were estimated from COS-7 cells ligand binding assay as
described under ‘‘Section 4’’. All assays were done in triplicates. Values are
mean ± SEM from 3 experiments.
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IL-8 (Fig. 5). This suggests that replacement of the highly conserved
D134 with N and V might impair the folding of the receptor that is
necessary for ligand binding and subsequent signaling efﬁcacy.
2.4. Identiﬁcation of CXCR1 mutants M241V and F251H possessing
constitutive activity
CXCR1 is coupled to both PTX-sensitive Gai2 as well as
PTX-resistant Ga15 in transfected COS-7 cells [37]. Mutation inD134 of DRY motif of CXCR1 did not retain G protein coupling or
agonist-induced response (Fig. 6). Despite the high sequence
identity between CXCR2 and KSHV-GPCR, both capable of binding
IL-8 with high afﬁnity, our results suggest that the conservative D
on DRY motif plays a distinct role in G protein coupling from these
two receptor homologues. This is probably responsible for the
unique regulation and activation of effectors triggered by binding
to IL-8. In contrast, among mutants detected compared with WT
CXCR1, individual replacement of methionine (M241V) and
phenylalanine (F251H) increased basal signal activity by 43.4%
and 46.1%, respectively, in the absence of IL-8 (p < 0.001 vs. WT
without IL-8 treatment), but not agonist-stimulated IP accumulation
of the receptor. This suggests that substitution of M241V and
Fig. 5. Binding of 125I-labeled IL-8 to COS-7 cells expressing WT CXCR1 and
mutants. The CXCR1 mutants were transiently transfected in COS-7 cells. Maximal
binding assay (A) and competition binding experiments (B) were performed as
described under ‘‘Section 4’’. (A) Maximal binding of 125I-IL-8 to CXCR1 WT and
mutants. Mock was transfected with pSG5 plasmid. (B) Competitive binding studies
were conducted using 125I-labeled IL-8 and various unlabeled ligands as described
under ‘‘Section 4’’. Nonspeciﬁc binding was determined by adding 250 nM
unlabeled IL-8. The ﬁgure shows representative maximal binding and competitive
binding experiments for the indicated CXCR1 mutants, performed in triplicate. Data
are mean ± SEM of replicate wells from a representative experiments performed in
triplicate. Curve ﬁtting was done using GraphPad Prism data analysis program, and
the afﬁnity constants (Kd) for CXCR1 mutants are shown in Table 1.
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M241V6.34 increased the IP accumulation basally as well as in
response to IL-8 in a dose-dependent manner (Fig. 7). Moreover,
in the absence of IL-8, IP accumulation was signiﬁcantly higher
in cells expressing M241V (p < 0.001) (Fig. 7). Two mutations onFig. 6. CXCR1 mutants coupled to Ga15. Basal and IL-8-stimulated inositol
phosphate (IP) accumulation is shown in COS-7 cells transiently co-transfected
with WT or mutant CXCR1 and pSG5 or Ga15. The release of inositol phosphate,
induced by 40 nM IL-8, was measured 1 h after the treatment. Data for mutants are
summarized from 3–7 experiments, each performed in triplicate, and are expressed
as a percentage of WT CXCR1 baseline determined in parallel. The results are
mean ± SEM. ⁄⁄P < 0.001, vs. WT + Ga15 (in the absence of IL-8).V247 (TM6:40), V247A and V247N, displayed constitutive activity
as reported recently [36]. Although F251A mutant showed
increased ligand afﬁnity, it was nearly dysfunctional, which is
likely attributed to its instability and its poor expression on cell
surface (Figs. 3–5).
2.5. Ability of CXCR1 WT and mutants to activate Gai
To examine their coupling to Gai protein, WT CXCR1 and
mutants were co-transfected into COS-7 cells with Gai2, Gb1,
Gc2 and PLCb2. This ﬁve-component co-transfection system
(Gai2-Gb1-Gc2-PLCb2) has been successfully applied to investi-
gate IL-8 signaling pathways in previous studies by our group
and others [36,37]. This unique co-transfection system allows
Gai2 activation in response to IL-8, leading to the release of Gbc
subunits from Gai2 and resulting in PLCb2 activation and subse-
quent IP accumulation. Our results showed that mutants S132A,
M241V, F251H and F251Y stimulated IP accumulation in response
to IL-8, similar to CXCR1 WT (Fig. 8C). IP production in response to
IL-8 was totally abolished by PTX, a speciﬁc inhibitor of Gai, sug-
gesting that CXCR1 and its mutants investigated here are coupled
to Gai2 (Fig. 8A and B). In contrast, IP production was mostly
retained in response to IL-8 when Ga15 was expressed (data not
shown). Thus, IP accumulation could be achieved via the PTX-in-
sensitive Ga15 pathway or the PTX-sensitive Gai2 pathway.
The low transfection rate in cells co-transfected with ﬁve differ-
ent components is probably caused by inherent difﬁculty in
simultaneous transfection with ﬁve vectors, which may account
for the low reading of IP accumulation. The coupling of CXCR1
and mutants to Gai was further demonstrated by introducing the
chimeric G protein, Gaqi5, which contains the main structure of
Gaq with the last ﬁve C-terminal amino acids of Gaq replaced with
the corresponding amino acids from Gai2. Gaqi5 allows Gai
protein-coupled receptors to participate in PLC-mediated signal
pathways, and such Gaqi5-mediated IP production has been used
to assess Gai-mediated signaling [36,38,39]. As shown in Fig. 8C,
IP production by CXCR1 WT, S132A, M241V, F251H and F251Y
was stimulated in response to IL-8 in Gaqi5-expressing cells, sug-
gesting that CXCR1 WT and these mutants are indeed coupled to
Gai protein. M241V and F251H constitutively activate Ga15 pro-
tein (Fig. 5). We observed a slight increase in basal IP accumulation
in Gaqi5-co-transfected cells for M241V (p < 0.001 vs. WT without
IL-8 treatment) and for F251H (p < 0.001 vs.WT without IL-8 treat-
ment) (Fig. 8B). Based on the results we draw the conclusion that
M241V and F251H are constitutively active mutants coupled to
both Ga15 and PTX-sensitive Gai protein.3. Discussion
Studies of GPCR crystal structures have revealed the role of DRY
motif in stabilizing GPCR conformation through formation of
hydrogen and ionic bonds with other amino acid residues that
impact GPCR activation and G protein coupling [17,18,40–43].
Substitution mutations of Asp1343.49 to asparagine (D134N) or
valine (D134V) resulted in nonfunctional receptors that were
devoid of ligand binding. Similar ﬁndings have been reported in
TM 3.49 of GPCRs such as rat angiotensin II (Ang II) receptor type
1A (AT1A) [44], vasopressin V1a receptor (V1aR) [45], muscarinic
receptor [46], and cannabinoid 2 (CB2R) [47,48]. Although D134
mutants are expressed on the surface of transfected cells, they
barely bind to the ligand IL-8, suggesting that inactivity of D134
mutants could be due to impaired receptor folding. Recent data
indicates that CXCR1 activity involves binding of IL-8 at two
distinct receptor sites (N-terminal residues, and extracellular
loop/transmembrane residues of receptor) and that coupling
Fig. 7. Constitutive activation of CXCR1 mutant M241V. Basal and IL-8-stimulated inositol phosphate (IP) accumulation is shown in COS-7 cells transiently co-transfected
with CXCR1 WT or mutant and Ga15. The cells were treated with various concentrations of IL-8. IP production was determined as described under ‘‘Section 4’’. Data are
mean ± SEM of replicate wells from a representative experiments performed in triplicate. Cells transfected with WT CXCR1 have the same basal IP production as cells
transfected with vector alone. ⁄P < 0.001, vs. WT + Ga15 (in the absence of IL-8).
Fig. 8. CXCR1 and mutants coupled to Gai2. (A) COS-7 cells were co-transfected
with equal amounts of cDNA (0.1 lg per well per component) encoding Gai2, Gb1,
Gc2, PLCb2, as well as WT CXCR1 or its mutants. (A and B) The inﬂuence of PTX on
the release of inositol phosphates. The cells were treated with or without PTX
(100 ng/ml) for 18 h as indicated. The release of inositol phosphates was measured
1 h after the treatment in the absence (A) or presence (B) of 40 nM IL-8. ‘‘M’’
denotes cells co-transfected with cDNA components encoding Gai2, Gb1, Gc2, and
PLCb2. (C) COS-7 cells were co-transfected with 0.3 lg of cDNA encoding Gaqi5 and
the WT CXCR1 or its mutants. The release of inositol phosphates, induced by 40 nM
IL-8, was measured 1 h after the treatment as described in detail under ‘‘Section 4’’.
Data are mean ± SEM of replicate wells from a representative experiment.
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Considering mutations such as D to N result in loss of speciﬁc
electrostatic interactions, it is possible that D134 mediates
coupling between these two sites that is disrupted in the mutants.Given that CXCR1 and CXCR2 share 77% amino acid identity and
can both bind to IL-8 and initiate chemotaxis and innate immune
response, it is unusual that the conserved D134 of CXCR1 plays a
distinct role in ligand binding and G protein coupling. This is
because CXCR1 is a close homologue to KSHV-GPCR and CXCR2.
Importantly, a mutation (D142V) within its DRY motif at the
junction of TM3 and i2 loop renders KSHV-GPCR constitutively
active, which is responsible for Kaposi’s sarcoma development
[26]. It is known that the exchange of Asp138 of the DRY sequence
in the CXCR2 with a Val (D138V) (the corresponding amino acid in
KSHV-GPCR) results in constitutive activity of CXCR2 and high
levels of inositol phosphate accumulation [25]. Our data suggest
that the conserved aspartic acid residue within the DRY motif of
CXCR1 plays a role in G protein coupling and receptor activation
that is distinct from that of KSHV-GPCR and CXCR2. These insights
will have important implications in identifying the critical amino
acid residues or motifs that are responsible for the selective activa-
tion of CXCR1 and CXCR2, and to elucidate distinct functional
mechanisms based on structural differences between CXCR1 and
CXCR2. Interestingly, an earlier study suggested that KSHV-GPCR
originated from CXCR1 or CXCR2 [50] during viral evolution. The
similarity in the signaling of the CXCR2 mutant D138V and the
KSHV-GPCR supports the hypothesis that KSHV-GPCR and CXCR2
share the same genetic origin [25]. Our results show a distinct role
of the conserved D1343.49 on DRY motif in receptor activation
between CXCR1 and its homologues (CXCR2 and KSHV-GPCR),
another evidence that KSHV likely originated from CXCR2 rather
than CXCR1.
Our recent study highlighted the important role of amino acid
residues on TM3 and TM6, especially those near intracellular loop
of CXCR1, in G protein coupling and receptor activation [36]. Other
188 X. Han et al. / FEBS Open Bio 5 (2015) 182–190recent studies on agonist-bound adenosine A2A receptor and
rhodopsin structures revealed that the cytoplasmic end of TM6
partially occludes the G-protein-binding site [19,51], suggesting
an essential role of the cytoplasmic end of TM6 in G protein cou-
pling and receptor activation. The comparison of agonist-bound,
active-state crystal structure and inactive structure of the human
beta2 adrenergic receptor and human A2A adenosine receptor
demonstrated an outward movement of the cytoplasmic end of
transmembrane segment 6 in the active form of the receptor that
are remarkably similar to those observed between active rhodop-
sin and inactive opsin [17,19,41,42,52]. In fact, many constitutively
active mutations of GPCRs are found in the bent region at the
cytoplasmic end of TM6, particularly in position 6.34, suggesting
that this region plays an important role in receptor activation.
Mutations on 6.34 site of M5 receptor [53], rat l-opioid receptor
[54], luteinizing hormone receptor [55], thyrotropin receptor
[56], and b(1)-adrenergic receptor [20] may generate different
degrees of constitutive activity. In addition, highly conserved
F2516.44 on TM6 is a key switch residue involved in activation,
and mutation on this site in TSH receptor and in LH receptor
caused constitutive activation [32,57]. In accordance, our ﬁndings
indicate that substitution of M2416.34 with Val and F2516.44 with
His caused constitutive activity of the receptor, indicating that
these conserved amino acids are critical for maintaining the
inactive conformation structure of CXCR1 and that mutations on
M2416.34 and F2516.44 may disrupt the constrained inactive
conformation and result in the constitutive activation of CXCR1.
We recently reported that V2476.40 is critical in CXCR1
activation and that mutations on V2476.40 result in constitutive
activation of CXCR1 [36]. In comparison, the two mutants from
the current study, M241V and F251H, showed modest constitutive
activity. V247A and V247N are potent mutants with constitutive
activity which caused the basal IP production to be increased by
78% and 130%, respectively, compared with CXCR1 WT. On the
other hand, IP production was increased by 43% and 46% for
M241V and F251H, respectively, compared with CXCR1 in the
absence of IL-8. M2416.34, V2476.40, and F2516.44 share spatial
proximity and are all located at the junction of TM6 and i3 loop
of CXCR1. The intracellular loops of GPCRs are crucial for G-protein
interactions [22]. The i3 loop of CXCR1, extending from Thr 228 to
Gln 236, protrudes into the cytoplasm where it is available for
G-protein binding [15]. The fact that different degrees of
constitutive activity of CXCR1 can result from mutations of either
M241, V247, or F251 on TM6 support the concept that an agonist
needs to disrupt just one key intramolecular interaction to stabilize
the inactive state of CXCR1, and trigger interaction with G proteins.
Our results suggest that regions containing M241, V247, F251 (and
probably other surrounding amino acid residues) on TM6,
especially those near i3 loop are ‘‘hot spots’’ for stabilizing the
inactive conﬁguration of CXCR1 critical for G protein activation
and receptor function.
Despite recent demonstration of the structure of resting CXCR1
by NMR [15], the critical structural information of CXCR1, espe-
cially ligand-bound as well as G protein-bound inactive and active
forms of CXCR1, are not available. We identiﬁed a critical amino
acid residue (D1343.49) on conserved glutamic acid/aspartic acid–
arginine–tyrosine (i.e., the E/DRY) triplet motif at the boundary
between TM3 and intracellular loop 2 of class A GPCRs (rhodopsin
family) that demonstrated distinct roles in G protein coupling and
receptor activation between CXCR1 and its homologues (CXCR2
and KSHV-GPCR). The D1343.49 within the evolutionarily conserved
E/DRY motif is important for protein stabilization and/or G protein
activation [21,22,58,59]. We showed that, unlike CXCR2 and
KSHV-GPCR, substituting the D1343.49 of DRY motif of CXCR1 with
N and V results in an almost silent receptor devoid of G protein
coupling that was strongly impaired in its ability to bind IL-8. Incontrast, mutations on M2416.34 (M241V) and F2516.44 (F251H)
led to modest constitutive activation of CXCR1, suggesting that
M2416.34 and F2516.44 play a role in stabilizing CXCR1 in the
ground (inactive) state and that disruption of intramolecular
constrains caused by introducing a residue may lead to
constitutive activation of CXCR1. The critical amino acid residues
identiﬁed in this study together the important residues that we
previously identiﬁed on CXCR1, provide new insights into ligand
binding, G protein coupling, as well as receptor activation of
CXCR. This knowledge will hopefully lead to better understanding
of the receptor structure and function so that novel and selective
agonists/antagonists could be designed for the treatment of
COPD or other inﬂammatory diseases caused by the excessive
neutrophil activation as well as for the disruption of breast cancer
stem cells.4. Materials and methods
4.1. Construction of expression vectors and site-directed mutagenesis
Wild type (WT) human CXCR1 cloned into pSFFVneo vector
was provided as a gift from Professor Ingrid Schraufstatter at the
La Jolla Institute for Experimental Medicine. After digestion with
EcoRI, WT human CXCR1 fragment was subcloned into the pSG5
vector. Oligonucleotides for site-directed mutagenesis were
designed to yield several different amino acid substitutions and
were synthesized by Invitrogen (Carlsbad, CA). CXCR1 mutations
were generated with the Transformer mutagenesis kit (Clontech,
Palo Alto, CA) and the ﬁnal constructs were conﬁrmed by Big Dye
Terminator Cycle Sequencing (Perkin Elmer). Plasmid DNA for
transient transfection was puriﬁed with the EndoFree Plasmid
Maxi Kit from Qiagen.
4.2. Transient transfection
COS-7 cells and human embryonic kidney 293 cells (HEK293
cells) from the American Type Culture Collection (ATCC,
Rockville, MD) were maintained at 37 C in humidiﬁed air contain-
ing 5% CO2 in DMEM with 10% FBS. Cells were grown to 6080%
conﬂuency prior to transient transfection. Transfection was per-
formed using LipofectAMINE reagent (Invitrogen, Carlsbad, CA)
according to the manufacturer’s instruction. COS-7 cells were incu-
bated with the transfection complex for 5 h at 37 C. After removal
of the transfection medium, the cells were incubated in DMEM
with 10% FCS overnight.
4.3. Flow cytometry
HEK 293 cells were transfected with either pSG5 plasmid, or
CXCR1 WT or mutants. After 48 h, cells were dissociated and ﬁxed
with 4% paraformaldehyde. Cells were then washed three times
with cold stain buffer before incubation on ice for 20 min with
mouse anti human CD128 FITC (CXCR1) from BD Biosciences
(Cat# 555939) (San Diego, CA). Cells were washed three times
and resuspended in 0.5 ml of stain buffer. Stained cell samples
were analyzed by ﬂow cytometry [36].
4.4. Confocal microscopy
COS-7 cells were transfected with either pSG5 plasmid, or
CXCR1 WT or mutants. After 24 h, cells were ﬁxed with 4%
paraformaldehyde followed by blocking with 1% BSA in HBSS.
Cells were incubated with primary antibody (mouse anti human
CD128a (CXCR1)) from BD Pharmingen (San Diego, CA) at 4 C
overnight. After washing three times, the cells were incubated with
X. Han et al. / FEBS Open Bio 5 (2015) 182–190 189the secondary antibody (Alexa Fluor 488, goat anti-mouse
IgG(H + L) from Invitrogen, CA) at RT for 1 h and counterstained
with Dapi. Expression of CXCR1 or the mutants was observed using
confocal microscope.
4.5. Inositol Phosphate (IP) Assays
Inositol Phosphate (IP) Assays was conducted as we previously
described [36]. Brieﬂy, COS-7 cells were plated in 24-well plates
with a density of 1  105 cells per well the day before transfection.
The cells were co-transfected with 0.3 lg CXCR1 plasmid DNA (or
its mutants) and 0.3 lg Ga15 (or Gaqi5) plus 1.5 ll LipofectAMINE
reagent and 0.5 ll Plus reagent. In experiments of co-transfection
with WT CXCR1 or its mutants and plasmids encoding Gai2, Gb1,
Gc2 and phospholipase C (PLC)b2, COS-7 cells were co-transfected
with equal amounts of cDNA (0.1 lg per well per component).
24 h after transfection, cells were incubated with inositol-free
medium containing 2 ll/ml myo-[2-3H] inositol (Dupont-NEN,
Boston, MA) in the absence or presence of 100 ng/ml pertussis
toxin (PTX) as indicated for 18 h. At 48 h from the start of transfec-
tion, cells were washed with assay buffer [Hank’s balanced salt
solution, 0.5% (w/v) crystalline bovine serum albumin, 20 mM
HEPES-NaOH, pH 7.4]. IP production was measured as described
before [36]. All assays were performed in triplicate, on at least 3
separate occasions with different batches of cells, and always
included control cells transfected with WT CXCR1. Data were
analyzed using GraphPad Prism (San Diego, CA) and expressed
as fold-increase over basal conditions in cells co-transfected with
WT CXCR1 and Ga15 plasmid.
4.6. IL-8 binding assay
IL-8 binding assay was conducted as described [36]. COS-7
cells were plated in 12-well plates at a density of 1.6  105 -
cells/ml of DMEM/10% FCS and incubated overnight. The cells
were transfected with 0.7 lg DNA plus 2.5 ll of LipofectAMINE
reagent and 5 ll Plus Reagent (total transfection volume was
0.5 ml/well). After 48 h from the start of transfection, transfected
cells were washed in the binding buffer (HBSS medium contain-
ing 0.5% BSA and 25 mM HEPES buffer) and then incubated for
2 h at 4 C. The ﬁnal concentration of 125I-IL-8 in the 0.5 ml/well
(for 12-well plate) of medium was 0.07 nM (0.05 lCi). The range
of unlabeled IL-8 concentrations in the binding assays was
0.1–300 nM [0, 0.1, 0.3, 1, 3, 10, 30, 100, 300 nM]. Non-speciﬁc
125I-IL-8 binding was determined by incubating the cells with
125I-IL-8 in the presence of 250 nM of cold IL-8. For maximal
binding of 125I-IL-8 to CXCR1 WT and mutants, unlabelled
IL-8 was not added. After washing three times with 2 ml of
ice-cold binding buffer, the cells were lysed in 0.5 ml of 1 N
NaOH and the lysates were counted using a scintillation counter.
The data were curve ﬁtted and afﬁnity constant (Kd) and maxi-
mum total binding (Bmax) values were calculated using
GraphPad Prism (San Diego, CA). All experiments were carried
out in triplicate.
4.7. Statistical analysis
Results were expressed as mean ± standard error of the mean
(SEM) from n determinations. Statistical analyses were performed
with GraphPad Prism 5.1 software. The signiﬁcance of differences
between the means was determined with the Student’s two tailed
t test. Values of p < 0.05 were considered as statistically signiﬁcant
and are denoted with an asterisk (*): ⁄p < 0.05; ⁄⁄p < 0.01. All the
experiments were repeated at least three times and each point
was tested in triplicate.Author contributions
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